Otsuka Holdings Co., Ltd. (OTSKY)
USD 27.55
(-0.4%)
USD 27.55
(-0.4%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2018.56 Billion JPY | 16.14% |
| 2022 | 1737.99 Billion JPY | 16.0% |
| 2021 | 1498.27 Billion JPY | 5.3% |
| 2020 | 1422.82 Billion JPY | 1.9% |
| 2019 | 1396.24 Billion JPY | 8.07% |
| 2018 | 1291.98 Billion JPY | 4.2% |
| 2017 | 1239.95 Billion JPY | 3.71% |
| 2016 | 1195.54 Billion JPY | -17.28% |
| 2015 | 1445.22 Billion JPY | -9.64% |
| 2014 | 1599.42 Billion JPY | 31.31% |
| 2013 | 1218.05 Billion JPY | 5.5% |
| 2012 | 1154.57 Billion JPY | 5.9% |
| 2011 | 1090.21 Billion JPY | 0.55% |
| 2010 | 1084.29 Billion JPY | 13.43% |
| 2009 | 955.94 Billion JPY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 589.41 Billion JPY | 13.45% |
| 2024 Q1 | 519.51 Billion JPY | -3.7% |
| 2023 Q4 | 539.48 Billion JPY | 1.49% |
| 2023 Q1 | 448.34 Billion JPY | -4.99% |
| 2023 Q2 | 499.19 Billion JPY | 11.34% |
| 2023 Q3 | 531.54 Billion JPY | 6.48% |
| 2023 FY | 2018.56 Billion JPY | 16.14% |
| 2022 Q3 | 451.81 Billion JPY | 4.1% |
| 2022 Q4 | 471.87 Billion JPY | 4.44% |
| 2022 FY | 1737.99 Billion JPY | 16.0% |
| 2022 Q1 | 380.3 Billion JPY | -2.7% |
| 2022 Q2 | 433.99 Billion JPY | 14.12% |
| 2021 FY | 1498.27 Billion JPY | 5.3% |
| 2021 Q3 | 388.6 Billion JPY | 1.72% |
| 2021 Q4 | 390.85 Billion JPY | 0.58% |
| 2021 Q2 | 382.02 Billion JPY | 13.43% |
| 2021 Q1 | 336.78 Billion JPY | -5.36% |
| 2020 Q3 | 371.51 Billion JPY | 4.39% |
| 2020 Q2 | 355.88 Billion JPY | 4.81% |
| 2020 FY | 1422.82 Billion JPY | 1.9% |
| 2020 Q1 | 339.56 Billion JPY | -7.6% |
| 2020 Q4 | 355.86 Billion JPY | -4.21% |
| 2019 Q3 | 357.62 Billion JPY | 0.13% |
| 2019 FY | 1396.24 Billion JPY | 8.07% |
| 2019 Q4 | 367.48 Billion JPY | 2.76% |
| 2019 Q2 | 357.17 Billion JPY | 13.77% |
| 2019 Q1 | 313.95 Billion JPY | -8.71% |
| 2018 Q3 | 329.74 Billion JPY | 1.88% |
| 2018 Q2 | 323.67 Billion JPY | 9.85% |
| 2018 Q4 | 343.9 Billion JPY | 4.29% |
| 2018 FY | 1291.98 Billion JPY | 4.2% |
| 2018 Q1 | 294.65 Billion JPY | -8.19% |
| 2017 Q3 | 323.66 Billion JPY | 2.69% |
| 2017 FY | 1239.95 Billion JPY | 3.71% |
| 2017 Q4 | 320.93 Billion JPY | -0.84% |
| 2017 Q2 | 315.16 Billion JPY | 12.48% |
| 2017 Q1 | 280.19 Billion JPY | -4.29% |
| 2016 Q2 | 307.38 Billion JPY | 8.78% |
| 2016 Q4 | 292.75 Billion JPY | -3.2% |
| 2016 FY | 1195.54 Billion JPY | -17.28% |
| 2016 Q3 | 302.43 Billion JPY | -1.61% |
| 2016 Q1 | 282.58 Billion JPY | -16.42% |
| 2015 FY | 1445.22 Billion JPY | -9.64% |
| 2015 Q4 | 338.07 Billion JPY | -6.44% |
| 2015 Q3 | 361.34 Billion JPY | 0.17% |
| 2015 Q2 | 360.72 Billion JPY | -6.32% |
| 2015 Q1 | 385.07 Billion JPY | 0.0% |
| 2014 Q2 | 386.34 Billion JPY | 2.99% |
| 2014 Q1 | 375.12 Billion JPY | -0.82% |
| 2014 FY | 1599.42 Billion JPY | 31.31% |
| 2014 Q3 | 401.93 Billion JPY | 4.04% |
| 2013 Q1 | 325.49 Billion JPY | 10.88% |
| 2013 Q2 | 323.52 Billion JPY | -0.6% |
| 2013 Q4 | 378.22 Billion JPY | 0.62% |
| 2013 Q3 | 375.88 Billion JPY | 16.18% |
| 2013 FY | 1218.05 Billion JPY | 5.5% |
| 2012 Q4 | 293.55 Billion JPY | -5.61% |
| 2012 FY | 1154.57 Billion JPY | 5.9% |
| 2012 Q3 | 311 Billion JPY | 7.99% |
| 2012 Q2 | 288 Billion JPY | 5.46% |
| 2012 Q1 | 273.1 Billion JPY | -6.21% |
| 2011 Q3 | 301.88 Billion JPY | 4.68% |
| 2011 Q4 | 291.18 Billion JPY | -3.54% |
| 2011 Q2 | 288.4 Billion JPY | 14.4% |
| 2011 Q1 | 252.09 Billion JPY | -4.55% |
| 2011 FY | 1090.21 Billion JPY | 0.55% |
| 2010 Q4 | 264.12 Billion JPY | -9.63% |
| 2010 Q1 | 266.82 Billion JPY | 1.23% |
| 2010 Q2 | 281.73 Billion JPY | 5.59% |
| 2010 Q3 | 292.25 Billion JPY | 3.73% |
| 2010 FY | 1084.29 Billion JPY | 13.43% |
| 2009 Q2 | 260.83 Billion JPY | 0.0% |
| 2009 Q4 | 263.58 Billion JPY | -10.05% |
| 2009 Q3 | 293.03 Billion JPY | 12.35% |
| 2009 FY | 955.94 Billion JPY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AstraZeneca PLC | 46.91 Billion USD | -4202.634% |
| Bristol-Myers Squibb Company PFD CONV 2 | 45 Billion USD | -4385.109% |
| CSPC Pharmaceutical Group Limited | 31.45 Billion USD | -6318.318% |
| Clarus Therapeutics Holdings, Inc. | 13.95 Million USD | -14462664.204% |
| Novartis AG | 46.66 Billion USD | -4226.121% |
| PT Kalbe Farma Tbk. | 1.97 Billion USD | -101889.41% |